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Background: Blockade of the cytokine interleukin-1 (IL-1) with IL-1 receptor antagonist (IL-21 
1Ra) is a candidate treatment for stroke entering phase II/III trials, which acts by inhibiting 22 
harmful inflammatory responses.  Infection is a common complication after stroke that 23 
significantly worsens outcome and is related to strke-induced deficits in systemic immune 24 
function thought to be mediated by the sympathetic nervous system.  Therefore, 25 
immunomodulatory treatments for stroke, such as IL-1Ra, carry a risk of aggravating stroke-26 
associated infection. Our primary objective was to determine if factors associated with 27 
antibody-mediated antibacterial defences were further compromised in patients treated with 28 
IL-1Ra after stroke. 29 
Methods: We assessed plasma concentrations of immunoglobulin isotypes and complement 30 
components in stroke patients treated with IL-1Ra or placebo and untreated non-stroke controls 31 
using multiplex protein assays. Activation of the sympathetic nervous system (SNS) was 32 
determined by measuring noradrenaline, a major SNS mediator. 33 
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Results:  There were significantly lower plasma concentrations of IgM, IgA, IgG1 and IgG4 34 
in stroke-patients compared to non-stroke controls, however there were no differences between 35 
stroke patients treated with placebo or IL-1Ra. Concentrations of complement components 36 
associated with the classical pathway were increased nd those associated with the alternative 37 
pathways decreased in stroke patients, neither being affected by treatment with IL-38 
1Ra.  Noradrenaline concentrations were increased aft r stroke in both placebo and IL-1Ra-39 
treated stroke patients compared to non-stroke controls.  40 
Conclusion: These data show treatment with IL-1Ra after stroke do s not alter circulating 41 
immunoglobulin and complement concentrations and is therefore unlikely to further aggravate 42 
stroke-associated infection susceptibility through altered availability of these key anti-43 
microbial mediators. 44 
 45 
Keywords 46 




Blocking the actions of the inflammatory cytokine iterleukin-1 (IL-1) using a highly selective 51 
IL-1 receptor antagonist (IL-1Ra) reduced injury and improved outcome in multiple 52 
experimental animal models of cerebral ischemia and is in ongoing clinical stroke trials 1-4.  53 
The inflammatory-modifying properties of IL-1Ra may confer protective effects to the brain 54 
after stroke; however, due to its potential for immunosuppression, it may also compromise 55 
systemic immune responses important for defence against infection. Systemic immune 56 
dysregulation is particularly important to consider in the context of stroke as patients are highly 57 
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susceptible to infection, which likely involves roles for stroke-induced impairments in some 58 
immune functions 5.   59 
We have previously shown deficits in early antibody responses, particularly IgM, associated 60 
with innate-like B cells in both experimental animals nd stroke patients, which may contribute 61 
to post-stroke infection susceptibility 6. IL-1β is reported to induce IgM production in innate-62 
like B cells 7; therefore, treatment with IL-1Ra may inhibit these important anti-microbial 63 
effects. We assessed whether markers associated with antibody-mediated antibacterial 64 
defences were compromised in patients treated with IL-1Ra after stroke. In summary, our data 65 
suggests treatment with IL-1Ra is unlikely to aggravate antibody-associated immune function 66 
deficits induced by stroke. 67 
 68 
Methods 69 
Standard protocol approvals, registrations, and patient consents 70 
This study involved tertiary analysis of plasma samples taken from a randomised, placebo-71 
controlled phase II trial originally designed to determine the safety and biological activity of 72 
intravenous (IV) IL-1Ra 4. The online clinical trials registries ClinicalTrials.gov and ISRCTN 73 
went live online during the year 2000, at which time online trial registration was a relatively 74 
new recommendation. The original IV IL-1Ra trial was set-up in 2000 and commenced 75 
February 2001 and therefore this trial was not officially registered. Furthermore, tPA 76 
recanalization therapy was not approved for use in the UK prior to 2003 for patients less than 77 
3 h from stroke onset, or 2013 for patients 3h to 4.5 h from stroke onset. Recruitment to the 78 
trial closed in July 2003 prior to widespread implementation of IV alteplase in the UK. 79 
Therefore no patients in this trial were given, or eligible for, recanalization therapy with tPA.  80 
Ethical approval for reanalysis of the samples was obtained through the Health Research 81 




Clinical trial protocol  84 
Participants and study procedures 85 
In brief, patients ≥ 18 years of age with a clinical diagnosis of stroke within six hours of stroke 86 
onset were eligible. Exclusion criteria included National Institutes of Health Stroke Scale 87 
(NIHSS) score of ≤ 4, pre-stroke modified Rankin Scale (mRS) score of ≥ 4 or rapidly 88 
improving neurological deficit. Patients were randomly assigned to treatment with recombinant 89 
methionylated human IL-1Ra (n=17) or placebo (n=17) stratified by age (< 70 and ≥ 70 years), 90 
baseline stroke severity (NIHSS score 4-9, 10-20, ≥ 21) and time since stroke onset (< 4 or ≥ 91 
4 h), but not by sex. IL-1Ra was initially administered as an IV loading dose of 100 mg over 92 
60 seconds, followed by 72 hours of consecutive infusions at 2 mg/kg/h. Full patient baseline 93 
characteristics and stratification of groups are provided as Extended data 33.  94 
Non-stroke control patients (n=13) of a similar age range with no previous history of stroke or 95 
transient ischemic attack were also recruited. Control patients were living independently at 96 
home, free of infection and able to provide written, informed consent. Controls were matched 97 
to stroke patients (six to patients receiving IL-1Ra and seven to patients receiving placebo) on 98 
a basis of age (±5 years), sex and degree of atheroscl sis which was determined using non-99 
invasive assessment of either ankle-brachial pressu or carotid atherosclerosis using doppler 100 
as previously described 8. 101 
 102 
Blood sampling 103 
Venous blood samples were collected prior to the initiation of treatment (admission), at the 104 
next 9 am time point (if admission was before 7 am or after 11 am), and then at 9 am at 24 105 
hours, 2 days, 3 days, 4 days and at 5-7 days after stroke, into tubes containing a final 106 
concentration of 10 µg/ml pyrogen-free heparin and wrapped in cool packs. Control patients 107 
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were sampled at 9 am and also at matched patient admission time (two hours) if this was not 108 
between 7 am and 11 am. Samples were centrifuged one hour after collection at 2000 xg for 30 109 
min at 4°C. Plasma was separated and frozen in aliquots at -70°C until further analysis. 110 
 111 
Luminex analysis of immunoglobulins and complement components 112 
Immunoglobulins and complement components were measur d in plasma samples using 113 
MILLIPLEX® multiplex assays. Patient details were blinded from samples and coded samples 114 
were randomised across plates for analysis. The MILLIP EX®MAP Human Isotyping Magnetic 115 
Bead Panel- Isotyping Multiplex Assay (HGAMMAG-301K-06, Merck Millipore Corporation, 116 
Billerica, MA, USA) was used to measure IgG1, IgG2, IgG3, IgG4, IgA and IgM. 117 
MILLIPLEX® MAP Human Complement Panel 1 (HCMP1MAG-19K, Merck Millipore 118 
Corporation) was used to measure C2, C4b, C5, C9, Mannose-binding lectin (MBL), Factor D 119 
(Adipsin) and Factor I. Many samples had concentrations of Factor D and Factor I below the 120 
detection range of the standard curve and so results for these analytes are not reported.  121 
MILLIPLEX® MAP Human Complement Panel 2 (HCMP2MAG-19K, Merck Millipore 122 
Corporation) was used to measure C1q, C3, C3b/ iC3b, 4, Factor B, Properdin and Factor H. 123 
Samples were assayed as singlets and all samples, standards and quality controls were prepared 124 
in accordance with the manufacturer’s instructions. Samples were incubated with beads on a 125 
plate for one hour (isotyping assay) or overnight (complement assays) at 4°C and washes 126 
carried out using a magnetic plate washer. Plates were analysed using a Magpix™ Luminex® 127 
machine and Luminex xPonent® software, version 4.2 with a sample volume of 50 ml per well 128 
and a minimum of 50 events counted per sample. 129 
 130 
Measurement of noradrenaline 131 
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Noradrenaline was measured in plasma samples using a Noradrenaline ELISA kit (BA E-5200; 132 
LDN®, Nordhorn, Germany). Patient details were blinded from samples and coded samples 133 
were randomised across plates for analysis. Samples were assayed as singlets and all samples, 134 
standards and quality controls were prepared in accordance with the manufacturer’s 135 
instructions, where noradrenaline is extracted from plasma using a cis-diol-specific affinity gel, 136 
acylated, enzymatically converted and then measured by ELISA. Optical density at 450 nm 137 
was measured using an MRX microplate Reader (Dynatech Labs, Chantilly, VA). 138 
 139 
Statistical analyses 140 
All immunoglobulin and complement components were measured in µg/ml and the D’Agostino 141 
and Pearson omnibus test was used to determine Gaussian distribution of sample data. As data 142 
were non-normally distributed, sample values were log10-transformed. The precise kinetics of 143 
individual patient responses were varied as demonstrated by analysing when minimum and 144 
maximum values were reached in individual patients for each time point, provided as Extended 145 
data. To overcome this variance, the maximal and minimal concentrations of each mediator in 146 
the first seven days after stroke were compared to non-stroke controls. Maximal and minimal 147 
concentrations from IL-1Ra-treated and placebo-treated stroke patients and non-stroke controls 148 
were compared by one-way ANOVA with Bonferonni correction. Each sampling time point 149 
was also compared to admission time point using a mixed models analysis with Dunnett 150 
correction in IL-1ra and placebo treated patients idividually, provided as Extended data.  151 
Noradrenaline concentrations were measured in ng/ml and the D’Agostino and Pearson 152 
omnibus test was used to confirm Gaussian distribution of sample data.  Maximal and minimal 153 
noradrenaline concentration from IL-1Ra-treated and placebo-treated stroke patients and non-154 
stroke controls were compared by one-way ANOVA with Bonferonni correction. Data analysis 155 
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was performed using GraphPad Prism 6.0 statistical an lysis software and for all experiments, 156 
values of P ≤ 0.05 were accepted as statistically significant.   157 
 158 





Plasma IgM concentration is reduced after stroke and is not affected by treatment with IL-1Ra  164 
Immunoglobulin M (IgM) is the predominant immunoglobulin isotype associated with early B 165 
cell antibody responses to infection by innate-like B cells, which we have previously shown to 166 
be depleted after experimental stroke in mice 6, 9, 10. Lower minimum concentrations of IgM 167 
were measured after stroke in comparison to non-stroke controls, and no difference was found 168 
between placebo and IL-1Ra treated patients. (Figure 1A) 32. Maximum IgM concentrations in 169 
the first seven days after stroke were also assessed and did not significantly differ in IL-1Ra or 170 
placebo treated patients in comparison to non-stroke controls (Supplementary Figure 1A, 171 
Extended data) 33. This indicates that the reduced minimum IgM concentration measured over 172 
the first seven days reflects an actual reduction in circulating IgM in stroke patients and is not 173 
an artefact of increased variance in IgM concentration after stroke. 174 
 175 
Plasma IgA, IgG1 and IgG4 concentrations are reduced after stroke and are not affected by 176 
treatment with IL-1Ra  177 
Minimum IgG1 concentration was significantly reduced in both placebo-treated and IL-1Ra-178 
treated stroke patients in comparison to non-stroke controls (Figure 1B) 32. Minimum IgG4 179 
(Figure 1C) and IgA (Figure 1D) concentrations were significantly reduced in placebo-treated 180 
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stroke patients only. However, there was no significant difference in these immunoglobulins 181 
between placebo-treated and IL-1Ra-treated patients. Minimum concentrations of IgG2 (Figure 182 
1E) and IgG3 (Figure 1F) were not significantly altered in IL-1Ra or placebo treated patients 183 
in comparison to non-stroke controls. Maximal circulating concentrations of all 184 
immunoglobulin isotypes measured in the first seven days after stroke were also compared to 185 
non-stroke controls and no significant differences were measured in any immunoglobulin 186 
isotypes (Supplementary Figure 1B-F, Extended data) 33.   The percentage of patients reaching 187 
their minimal circulating concentration at each sampling time point was compared in placebo 188 
and IL-1Ra treated groups and showed no impact of IL-1ra treatment on the kinetics of these 189 
responses (Supplementary Figure 5, Extended data). 190 
 191 
Concentrations of complement components are differentially affected by stroke and not 192 
affected by treatment with IL-1Ra  193 
As complement components are directly associated with the antibacterial functions of 194 
immunoglobulins, we investigated stroke-induced changes in circulating complement 195 
components and if any changes observed were further influenced by treatment with IL-1Ra.  196 
Stroke induced a significant reduction in the minimum concentrations of C3b/ iC3b (Figure 197 
2A), C3 (Figure 2B), C4 (Figure 2C), Factor H (Figure 2D) and Properdin (Figure 2E) 198 
measured in the first seven days after stroke in both placebo and IL-1Ra treated patients in 199 
comparison to non-stroke controls 32.  Maximum circulating concentrations of these 200 
complement components measured in the first seven days after stroke were also compared to 201 
non-stroke controls and no significant differences were seen (Supplementary Figure 2A-E, 202 
Extended data) 33.  The percentage of patients reaching their minimal circulating concentration 203 
at each sampling time point was compared in placebo and IL-1Ra treated groups and showed 204 
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no impact of IL-1ra treatment on the kinetics of these responses (Supplementary Figure 6, 205 
Extended data). 206 
 207 
In contrast, stroke induced a significant increase in maximal circulating concentrations of C1q 208 
(Figure 3A), C5 (Figure 3D) and C9 (Figure 3E) in both IL-1Ra and placebo treated patients 209 
measured in the first seven days after stroke in comparison to non-stroke controls. Maximum 210 
concentrations of C2 (Figure 3B) and C4b (Figure 3C) were increased in placebo-treated 211 
patients only 32. However, no significant difference was apparent between placebo treated and 212 
IL-1Ra treated patients for these factors, suggesting IL-1Ra treatment exerts no effects 213 
additional to stroke.  Minimum concentrations of these complement components measured in 214 
the first week after stroke were also compared to non-stroke controls and no significant 215 
differences were seen (Supplementary Figure 3A-E, Extended data) 33. The percentage of 216 
patients reaching their maximum circulating concentration at each sampling time point was 217 
compared in placebo and IL-1Ra treated groups and showed no impact of IL-1ra treatment on 218 
the kinetics of these responses (Supplementary Figure 7, Extended data). 219 
 220 
Minimal and maximal levels of Factor B, MBL and C5a measured in the first week after stroke 221 
were also compared to non-stroke controls. Concentrations of Factor B (Figure 4A, B) and 222 
MBL (Figure 4C, D) were not significantly altered by stroke or by treatment with IL-1-Ra 32.   223 
 224 
Plasma noradrenaline concentration is increased after stroke and is not affected by treatment 225 
with IL-1Ra 226 
Splenic noradrenaline levels are increased after experimental stroke and may be toxic to IgM 227 
producing B cells 6.  Maximum noradrenaline concentration measured in the first seven days 228 
after stroke was increased in both placebo and IL-1Ra treated patients in comparison to non-229 
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stroke controls (Figure 5A) 32. Treatment with IL-1Ra had no additional effect on noradrenaline 230 
concentration when compared to placebo. Minimum noradrenaline concentration in the first 231 
seven days after stroke was also measured and was not sig ificantly different to non-stroke 232 





In this study, we assessed if markers associated with antibody-mediated antibacterial defences 238 
were compromised in patients treated with IL-1Ra after stroke.  Plasma IgM, IgG1, IgG4 and 239 
IgA immunoglobulin concentrations were reduced after s roke and this was not further altered 240 
by treatment with IL-1Ra.  Assessment of complement components indicated increased 241 
concentration of components associated with the classic l pathway of complement activation 242 
in the first week after stroke but reduced concentration of those associated with the alternative 243 
pathway without modulation by IL-1Ra.  Plasma noradrenaline was increased after stroke and 244 
also not influenced by treatment with IL-1Ra.  245 
 246 
The IL-1 family of cytokines play a critical role in host defence to pathogens by signalling to 247 
a variety of host cells to induce downstream effects including, but not limited to, pro-248 
inflammatory cytokine and chemokine production, immune cell recruitment and upregulation 249 
of vascular adhesion molecules 11, 12.  However, in conditions of sterile inflammation ad tissue 250 
injury, such as stroke, these effects can aggravate primary tissue damage and impair injury 251 
repair mechanisms. Blocking IL-1 signalling has shown improved outcome in both 252 
experimental animal and patient stroke studies 1, 4, 13.  However, the immunosuppressive effects 253 
of blocking IL-1 signalling after stroke may additionally inhibit systemic responses to 254 
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infection, further increasing the risk of infection i  patients who are already immune 255 
compromised 14, 15.  Indeed, meta-analysis studies have shown an increased risk of serious 256 
infection in rheumatoid arthritis patients treated for prolonged periods with the IL-1 blocking 257 
drug anakinra 14. However, as of yet this has not been observed in stroke patients, potentially 258 
reflecting differences in the duration of treatment. No statistically significant differences in 259 
infection incidence were seen between IL-1Ra and placebo treated patients in this study, with 260 
5/17 IL-1Ra treated patients experiencing infection between admission and day seven and 4/17 261 
infections in placebo treated patients. Consistent with this pattern, we have shown here that 262 
relatively short duration of treatment with IL-1Ra after acute stroke did not further affect 263 
stroke-induced changes to circulating immunoglobulin, complement or noradrenaline 264 
concentrations and is therefore unlikely to further compromise immune defence against 265 
infection through altering the bioavailability of these antibacterial mediators.   266 
 267 
IL-1 cytokine family members are reported to have variable effects on B cell antibody 268 
production.  IL-1β was reported to be important for the rapid production of anti-bacterial IgM 269 
by innate-like B cells important for early containment of infection prior to the induction of 270 
adaptive immune responses 7, 16.  This would suggest treatment with IL-1Ra after stroke could 271 
further compromise the early production of IgM in in ate-like B cells which are already known 272 
to be reduced in number after stroke 6.  However, an effect of IL-1Ra on IgM concentration 273 
was not seen. Experimental stroke results in a significa t loss of many populations of B cells 274 
and associated IgM 6; therefore, it is possible that the effects of thestroke itself on B cells 275 
overwhelm any additional effects of cytokines that could moderately enhance or inhibit 276 
immunoglobulin production.  Furthermore, it is not known if remaining B cells are functionally 277 
impaired and therefore able to respond to IL-1β signalling as they would under normal 278 
homeostatic conditions. We have previously reported that stroke is associated with reduced 279 
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circulating IgM concentrations in comparison to non-stroke controls 6, an effect reproduced 280 
here.  Further studies will be required to determine if IgM, or any of the mediators assessed in 281 
this study, would be useful as biomarkers to determine which patients are likely to develop 282 
infection after stroke. 283 
 284 
We have shown for the first time that circulating IgG1, IgG4 and IgA concentrations were 285 
reduced in the first seven days after stroke in comparison to non-stroke controls. This is in 286 
agreement with previous data showing that pan-IgG concentrations were reduced in patients 287 
after stroke, although subclasses of IgG were not assessed in that study and no reduction in IgA 288 
was found at the seven day time point assessed 17. IgA is the most predominant 289 
immunoglobulin isotype at mucosal surfaces including the respiratory tract and is crucial for 290 
antibacterial protection at these sites 18. Given the early reduction of IgA in placebo-treated 291 
stroke patients, determining the effect of stroke on IgA-producing B cells at infection 292 
susceptible sites, such as the lung mucosa, could further elucidate if this has an important role 293 
in post-stroke infection susceptibility.   294 
 295 
In contrast to the short half-life of IgA and IgM 18-20, the half-lives of IgG1 and IgG4 are 296 
reported to be 21 days and therefore, an early reduction in IgG concentration is not compatible 297 
with a lack of de novo production after stroke due to loss of B cells 21.  Previous studies have 298 
suggested that reduced total-IgG after stroke may be associated with increased loss or 299 
catabolism of IgG, which could account for reductions in concentration occurring more rapidly 300 
than its natural half-life 22. An alternative explanation could be that reduced IgG concentration 301 
is indicative of vascular risk factors and inflammatory changes preceding stroke that are 302 
associated with stroke risk. However, control patients in this study were matched for risk 303 
factors including their degree of atherosclerosis and would be expected to show similar changes 304 
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to stroke patients if these were associated with risk factors. Understanding that the kinetics of 305 
an individual immunoglobulin subset changes both preceding and as a result of stroke, and 306 
their associations with post-stroke infections, could be invaluable in providing new therapeutic 307 
targets to reduce incidence of infection and improve utcome in patients. 308 
 309 
The complement system has a crucial role in enhancing humoral immune defence and 310 
protecting from bacterial infection via interactions with both the innate and adaptive immune 311 
systems 23.  As activation of the complement system is closely associated with efficient 312 
immunoglobulin-mediated clearance of pathogens, we determined whether complement 313 
mediators were altered by stroke. We have assessed, for the first time, individual concentrations 314 
of multiple complement components covering all pathways of complement activation after 315 
stroke. These data suggest there are no overall deficits in complement activation after stroke 316 
that could further compromise patient ability to fight infection.  Complement activation 317 
pathways converge at multiple points; however, their initial activation mechanisms are distinct. 318 
The classical complement pathway is activated when IgM or IgG immune complexes bind to 319 
C1 (composed of C1q, C1r and C1s) 23, 24. Maximum circulating concentration of complement 320 
components associated with the classical and lectin pathways of activation, C1q, C2 and C4b, 321 
and end stage mediators common to all pathways, C5 and C9, were increased in the first seven 322 
days after stroke in comparison to non-stroke controls.  In this study, concentration of MBL 323 
was not significantly altered by stroke, however other recognition molecules such as ficolins 324 
and collectin-11 which were not analysed in this study are also important initiators of the lectin 325 
pathway of complement activations 25.  Additionally, around 20% of the general population 326 
has a genetic deficiency in MBL associated with a circulating level of MBL < 500 ng/ ml.  To 327 
ensure our analysis of MBL concentration was not confounded by the inclusion of these genetic 328 
variants, patients who did not reach a circulating concentration of >500 ng/ ml across the entire 329 
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sampling time course were excluded from the analysis reducing our n to 15 patients per 330 
treatment group.  Therefore from these data, we cannot determine the individual contribution 331 
of the classical and lectin pathway of complement activ tion to the increased concentration of 332 
factors common to these two pathways in the first week after stroke. 333 
 334 
In contrast, the alternative pathway of complement activation is initiated by microbial cell 335 
surfaces and polysachharide antigen and results in a cascade that generates C3 23, 24.  336 
Complement components that were significantly downregulated after stroke, C3b/ iC3b, C3, 337 
Factor H (fH) and Properdin, are more associated with the alternative pathway of complement 338 
activation.  These data are in agreement with previous studies investigating systemic C-reactive 339 
protein, C3c and C4 complement concentrations in the serum of patients 24 h after ischemic 340 
stroke, which concluded that the classical pathway of complement activation was activated in 341 
the first 24 h after ischemic stroke, whereas C3c, associated with the alternative pathway, was 342 
reduced 26, 27. The roles of individual pathways of complement acivation in infection 343 
susceptibility after stroke remain to be determined, and we note that reduced concentrations of 344 
some complement mediators may reflect pathway activtion rather than suppression (e.g. via 345 
sequestration by binding to targets) therefore some caution is required in interpretation. 346 
Nonetheless, the data presented here show that IL-1Ra does not alter levels of mediators 347 
suggesting that functional effects of treatment on pathway activation or suppression are 348 
unlikely via altered bioavailability.  Furthermore, our data suggest that overall deficits in 349 
complement concentration are unlikely to contribute to reduced antibody-mediated clearance 350 
of pathogens that may occur after stroke.   351 
 352 
In this study, circulating noradrenaline concentrations measured in the first week after stroke 353 
were increased in comparison to non-stroke controls but were not influenced by treatment with 354 
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IL-1Ra. This is in agreement with previous studies showing activation of the sympathetic 355 
nervous system in both stroke and subarachnoid haemorrhage patients that resulted in increased 356 
plasma noradrenaline concentrations that persisted up to 10 days 28-30.  Our previous studies 357 
have shown that after experimental stroke, activation of the sympathetic nervous system and 358 
release of noradrenaline within the spleen is toxic to resident B cells and preventing 359 
noradrenaline signalling using the β-blocker propranolol prevented B cell and IgM loss and 360 
resulted in reduced infectious burden 6.  The cytokine IL-1β is also increased in the spleen after 361 
stroke and is reported to activate peripheral nerves, including the splenic nerve, and increase 362 
production of splenic noradrenaline 31, 32. However, blockade of IL-1β signalling did not alter 363 
circulating concentrations of noradrenaline after sroke.  364 
 365 
There are some limitations to our study. As this was a tertiary analysis of samples collected 366 
from the original study, designed to test the safety profile and biological activity of intravenous 367 
Il-1ra treatment after stroke, there are some caveats to the current analysis.  Firstly, blood 368 
samples were collected in heparin containing tubes, whereas collection in EDTA provides 369 
optimal conditions for subsequent measurements of complement components 33, 34.  Heparin is 370 
known to have an effect on baseline levels of comple ent components in serum as complement 371 
can spontaneously activate during the clotting process.  However, plasma from blood samples 372 
collected in EDTA or heparin were reported to have similar baseline levels of complement 373 
components.  The original sampling methods may have induced an increase in absolute 374 
measures of complement concentrations in this study, however samples were prepared as 375 
plasma, and all samples were collected by this method, any artefact of the heparin blood 376 
collection should be comparable across all samples and not affect the overall conclusions drawn 377 
from the data.   378 
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Additionally, due to the randomisation and blinding of patients during recruitment, there was 379 
an uneven balance of haemorrhagic stroke patients ver us ischemic stroke patients in the 380 
placebo and IL-1ra treated groups (0% and 29.4% respectively, Supplementary Table 1).  To 381 
determine if this bias had skewed the data in the IL-1ra treated group, we highlighted data 382 
points from haemorrhagic stroke patients in red to etermine their distribution within the IL-383 
1ra treated group for each mediator analysed.  In most cases, data points representing 384 
haemorrhagic stroke patients appeared evenly distributed throughout the data sets.  385 
Furthermore, excluding the haemorrhagic stroke patient data points from the statistical analysis 386 
did not change the interpretation of the results for each mediator.  This suggests that the uneven 387 
representation of haemorrhagic stroke patients in the IL-1ra treated group did not impact the 388 
overall conclusions in this study. However studies d igned to investigate the pathophysiology 389 
of immune suppression after stroke in different stroke subsets would be required to fully 390 
understand the extent to which stroke subtype can impact the extent of changes to the immune 391 
system. 392 
 393 
In summary, we have shown that treatment with IL-1Ra after stroke does not affect circulating 394 
concentrations of immunoglobulins, complement components or noradrenaline and is therefore 395 
unlikely to further increase patient susceptibility to infection via pathways in which these 396 
mediators are key participants. This aligns with data from IL-1Ra Phase II trials, in which 397 
treatment of stroke patients with IL-1Ra did not aggravate incidence of infection 4, 35. These 398 
data suggest that blocking IL-1 for short durations as applied in an acute stroke context may be 399 
relatively safe from the perspective of infection risk. Additionally, the treatment-independent 400 
reductions in circulating immunoglobulin concentrations detected after stroke in this study 401 
further support that antibody mediated immune defence may be an important therapeutic target 402 




Data availability 405 
Underlying data 406 
Edinburgh Data Share: Interleukin-1 receptor antagonist treatment in acute ischaemic stroke 407 
does not alter systemic markers of anti-microbial defence. https://doi.org/10.1101/587881  32 408 
This project contains the following underlying data: 409 
- Underlying data for noradrenaline analysis by each patient at each time point 410 
- Underlying data for complement mediator analysis by each patient at each time point 411 
- Underlying data for immunoglobulin analysis by each patient at each time point 412 
- Figure 1A dataset.pzf – Figure 5A dataset.pzf (raw data underlying Figures 1-5 in 413 
GraphPad Prism format) 414 
- Fig 1 data in Excel format for accessibility.xlsx (minimum concentrations of 415 
immunoglobulins) 416 
- Fig 2 data in Excel format for accessibility.xlsx (minimum concentrations of 417 
complement components C3b/iC3b, C3, C4, Factor H and Properdin) 418 
- Fig 3 data in Excel format for accessibility.xlsx (maximum concentrations of 419 
complement components C1q, C2, C4b, C5 and C9) 420 
- Fig 4 data in Excel format for accessibility.xlsx (concentrations of complement 421 
components Factor B and MBL) 422 
- Fig 5 data in Excel format for accessibility.xlsx (maximum concentrations of 423 
noradrenaline) 424 
Extended data 425 
Edinburgh Data Share: Supplementary Figures: Interleukin-1 receptor antagonist treatment in 426 
acute ischaemic stroke does not alter systemic markers of anti-microbial defence. 427 
https://doi.org/10.7488/ds/2545 33 428 
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This project contains the following extended data: 429 
- Supplementary Figure 1.tif (figure showing maximum concentrations of 430 
immunoglobulin) 431 
- Supplementary Figure 2.tif (figure showing maximum concentrations of complement 432 
components C3b/iC3b, C3, C4, Factor H and Properdin) 433 
- Supplementary Figure 3.tif (figure showing minimum concentrations of complement 434 
components C1q, C5, C9, C2 and C4b) 435 
- Supplementary Figure 4.tif (figure showing minimum concentrations of noradrenaline) 436 
- Supplementary Table 1.tif (table of baseline characteristics of stroke patients and 437 
stratification of groups) 438 
- Supplementary Figure 5.tif (figure showing at which time points patients reached their 439 
minimum circulating concentrations of immunoglobulin subsets) 440 
- Supplementary Figure 6.tif (figure showing at which time points patients reached their 441 
minimum circulating concentrations of complement comp nents significantly reduced 442 
after stroke) 443 
- Supplementary Figure 7.tif (figure showing at which time points patients reached their 444 
maximum circulating concentrations of complement comp nents significantly 445 
increased after stroke) 446 
- Supplementary Figure 8.tif (Immunoglobulin subclass concentrations at each sampling 447 
time point after stroke in placebo and IL-1ra treated patients) 448 
- Supplementary Figure 9.tif (Complement component cocentrations reduced 1-7 d after 449 
stroke at each sampling time point after stroke in placebo and IL-1ra treated patients) 450 
- Supplementary Figure 10.tif (Complement component co centrations increased 1-7 d 451 




- Supplementary Figure 11.tif (Complement component co centrations unchanged 1-7 d 454 
after stroke at each sampling time point after stroke in placebo and IL-1ra treated 455 
patients) 456 
- Data Supplementary Fig 1.xlsx - Data Supplementary Fig 4.xlsx (data underlying 457 
Supplementary Figures 1-4) 458 
- Data Supplementary Fig 5.xlsx (Supplementary Table 1 in spreadsheet format) 459 
- Immunoglobulin time course data Supplementary figures 5, 8.xlsx (data underlying 460 
Supplementary Figures 5 and 8)Complement time course data Supplementary figures 461 
6,7,9,10,11.xlsx (data underlying Supplementary Figures 6, 7, 9, 10 and 11) 462 
Data are available under the terms of the Creative Commons Attribution 4.0 International license 463 
(CC-BY 4.0). 464 
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Figure 1. Reduced plasma IgM, IgA, IgG1 and IgG4 after stroke is not affected by IL-1 receptor 567 
antagonist (IL-1Ra)   568 
(A) Minimum IgM concentration measured in the first seven days after stroke was lower in both placebo 569 
and IL-1Ra treated patients in comparison to healthy controls. Data show mean ±SD, * P<0.05, **  570 
P<0.01, one-way ANOVA with Bonferonni correction. (B) Minimum concentration of IgG1 and 571 
measured in the first seven days after stroke was reduced in both placebo and IL-1Ra treated patients 572 
in comparison to healthy controls. Minimum IgG4 (C) and IgA (D) concentrations were reduced in 573 
placebo-treated stroke patients in comparison to healthy controls. There was no significant difference 574 
between placebo-treated and IL-1Ra-treated stroke pati nts. No significant difference in IgG2 (E) and 575 
IgG3 (F) concentration was detected between placebo-treated and IL-1Ra-treated stroke patients in 576 
comparison to healthy controls.  Ischemic and haemorrhagic stroke patients are represented by black 577 
and red data points, respectively. Data show mean ±SD, * P<0.05; **  P<0.01; one-way ANOVA with 578 
Bonferonni correction. 579 
 580 
Figure 2. Treatment with IL-1 receptor antagonist (IL-1Ra) has no effect on complement 581 
components downregulated after stroke 582 
Minimum concentrations of (A) C3b/ iC3b, (B) C3, (C) C4, (D) Factor H and (E) Properdin were 583 
measured in the first seven days after stroke were reduced in both placebo and IL-1Ra treated patients 584 
in comparison to healthy controls. Ischemic and haemorrhagic stroke patients are represented by black 585 
and red data points, respectively.  Data show mean ±SD, * P<0.05; **  P<0.01; one-way ANOVA 586 
with Bonferonni correction. 587 
 588 
Figure 3. Treatment with IL-1 receptor antagonist (IL-1Ra) has no effect on complement 589 
components upregulated after stroke 590 
Maximum concentrations of (A) C1q, (B) C2, (C) C4b, (D) C5 and (E) C9 were measured in the first 591 
seven days after stroke were increased in both placebo and IL-1Ra treated patients in comparison to 592 
healthy controls. Ischemic and haemorrhagic stroke patients are represented by black and red data 593 
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points, respectively.  Data show mean ±SD, * P<0.05; **  P<0.01; one-way ANOVA with 594 
Bonferonni correction. 595 
 596 
Figure 4. Treatment with IL-1 receptor antagonist (IL-1Ra) has no additional effect on 597 
complement components unaffected by stroke 598 
Minimal and maximum concentrations of (A, B) Factor B and (C, D) mannose-binding lectin (MBL) 599 
were measured in the first seven days after stroke wer unchanged in both placebo and IL-1Ra treated 600 
patients in comparison to healthy controls. Ischemic and haemorrhagic stroke patients are represented 601 
by black and red data points, respectively.  Data show mean ±SD, one-way ANOVA with Bonferonni 602 
correction. 603 
 604 
Figure 5. Plasma noradrenaline concentration is increased after stroke and is not affected by 605 
treatment with IL-1 receptor antagonist (IL-1Ra) 606 
Maximal noradrenaline concentration measured in the first seven days after stroke was significantly 607 
higher in both placebo and IL-1Ra treated patients i  comparison to controls.  Ischemic and 608 
haemorrhagic stroke patients are represented by black and red data points, respectively.  Data show 609 
mean ± SD *P<0.05; **P<0.01; one-way ANOVA. 610 
 611 
 612 
 613 
